



**T R A N S F O R M**  
pharmaceuticals, inc.

Contact:

*ALZA Corporation*

(650) 564-5222

Ellen Rose

Kathy Kim

*Transform Pharmaceuticals*

(781) 926-8500

Barbara Carter

(212) 696-4455 x204

Ernie Knewitz

## **ALZA CORPORATION AND TRANSFORM PHARMACEUTICALS TO COLLABORATE ON DRUG OPTIMIZATION**

**MOUNTAIN VIEW, CA & WALTHAM, MA, June 5, 2002** --ALZA Corporation and TransForm Pharmaceuticals, Inc. today announced a major collaboration to develop more effective pharmaceutical products. Under the terms of the multiyear agreement, ALZA and TransForm have agreed to work together exclusively to develop and implement a proprietary high throughput platform to enable the rapid and efficient identification of optimal formulations for future products that employ ALZA's proprietary D-TRANS® transdermal delivery technology.

The collaboration brings together TransForm's state-of-the-art high-throughput capabilities, sophisticated informatics, and pharmaceuticals expertise in form and formulation with ALZA's industry-leading capabilities in drug delivery technology. Under the terms of the agreement, ALZA has paid TransForm an up-front licensing fee and will wholly fund the development of specialized, high throughput platforms that will be used to discover proprietary formulations for products. ALZA will pay TransForm milestones and royalties on the resulting formulations and products, and will develop and manufacture products arising from the collaboration.

"ALZA has long been visionary in the area of drug delivery. We're delighted they have chosen to work with TransForm in the formulation area," said Norman Selby, President and CEO of TransForm. "Our ability to perform high throughput discovery and analysis of pharmaceutical forms and formulations has the potential to create significant new opportunities for partners like ALZA interested in capturing the maximum value from their drug portfolios."

"We are excited to be collaborating with TransForm to bring together our leading capabilities. Our collaboration underscores ALZA's commitment to maintaining leadership in drug delivery and to expanding our partnerships throughout the global healthcare industry. Our collaborations with pharmaceutical, biotechnology and academic partners are helping to drive future innovations that will result in commercially differentiated products for patients worldwide." said Sam Saks, M.D., ALZA's company group chairman.

### **About ALZA Corporation**

ALZA Corporation, headquartered in Mountain View, California, is leading the next generation of drug delivery with the world's broadest array of technology platforms, including oral, transdermal, implantable and liposomal technologies. ALZA applies its delivery technology to develop and manufacture pharmaceutical products with enhanced therapeutic value for many of the world's leading pharmaceutical companies. More than 30 products marketed in over 80 countries worldwide now incorporate ALZA's drug delivery technologies. ALZA Corporation is a member of the Johnson & Johnson (NYSE:JNJ) family of companies. For further information, please go to ALZA's website at [www.alza.com](http://www.alza.com).

### **About TransForm Pharmaceuticals**

TransForm is reinventing the pharmaceutical industry's approach to form and formulation, with a novel set of high-throughput automated platform technologies, powered by state-of-the-art informatics and a scientific and managerial team with deep experience in pharmaceuticals. It uses these capabilities to optimize drug forms and/or formulations, and increase the clinical and commercial value of pharmaceutical products across the entire pharmaceutical value chain. In R&D, TransForm works with partners to help them make better candidate selection decisions, and reduce attrition and development time and cost. For later stage and marketed products, TransForm helps partners enhance product life cycle management by discovering new forms and/or formulations that optimize bioavailability and solubility, broaden intellectual property protection and create the potential for new dosage forms and/or combination products. TransForm is also using these capabilities to develop its own proprietary product portfolio. TransForm, founded in late 1999 with initial technology from Millennium Pharmaceuticals (NASDAQ:MLNM), is a privately held company located in Waltham, Massachusetts. For more information, please visit our website at [www.transformpharma.com](http://www.transformpharma.com).